Exposure to Valsartan Products Containing Nitrosamine Impurities in the <scp>U</scp>nited States, Canada, and Denmark
In this cohort study, despite widespread use of recalled generic valsartan between 2012 and 2018, the duration of use was relatively short and probably did not pose an elevated risk of nitrosamine-induced cancer. However, since products with nitrosamine impurity could have been on the market over a 6-year period, patients exposed to these products for longer durations could have a potentially different risk of cancer.
Authors
- Ashish Rai (ORCID: https://orcid.org/0000-0001-7131-7580)
- Peter Bjødstrup Jensen (ORCID: https://orcid.org/0000-0001-5435-9092)
- Laura Hou (ORCID: https://orcid.org/0000-0003-0847-2574)
- Daniel Scarnecchia (ORCID: https://orcid.org/0000-0001-9486-4974)
- Judith C. Maro (ORCID: https://orcid.org/0000-0001-9900-2142)
- Robert W. Platt (ORCID: https://orcid.org/0000-0002-5981-8443)
- Anton Pottegård (ORCID: https://orcid.org/0000-0001-9314-5679)
- Michael J. Paterson (ORCID: https://orcid.org/0000-0002-8526-9126)
- Efe Eworuke (ORCID: https://orcid.org/0000-0001-8971-9748)
- Hana Lee (ORCID: https://orcid.org/0000-0001-9497-0574)
- Marie C. Bradley (ORCID: https://orcid.org/0000-0002-3231-9951)
- Mayura Shinde
- Deborah G. Johnson
- Yuanling Liang
Institutions
- Center for Drug Evaluation and Research (US)
- Harvard University (US)
- University of Southern Denmark (DK)
- Canadians Living with HIV (CA)
- Harvard Pilgrim Health Care (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/pds.5849
- Citations
- 2
- Primary Topic
- Meat and Animal Product Quality
- Type
- article
- Field-Weighted Citation Impact
- 0.68
Funders
- U.S. Food and Drug Administration
- Canadian Institutes of Health Research